|
US2017042915A1
|
|
Lpa receptor modulators for brown fat differentiation
|
|
US2017014524A1
|
|
Auristatin-antibody conjugates and uses thereof
|
|
WO2016210345A1
|
|
Composition and methods for inhibiting mammalian sterile 20-like kinase 1
|
|
US2016324981A1
|
|
Liver x receptor agonists and uses thereof
|
|
WO2016168773A2
|
|
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
WO2016168766A1
|
|
Optimized chimeric receptor t cell switches and uses thereof
|
|
WO2016161176A1
|
|
Methods for treating viral infections
|
|
WO2016154621A1
|
|
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
CN107645955A
|
|
Therapeutic agent of modification and combinations thereof
|
|
WO2016123368A1
|
|
Methods of antibiotic treatment with metal-thiolate complexes
|
|
WO2016115218A1
|
|
Antibody drug conjugates for the treatment of immune conditions
|
|
CN107405505A
|
|
For treating the compound of cystic fibrosis
|
|
KR20170091154A
|
|
Small molecule inhibitors of fibrosis
|
|
WO2016054520A2
|
|
Engineered cell surface proteins and uses thereof
|
|
WO2015200349A2
|
|
Elastase inhibitors
|
|
US2017210818A1
|
|
Constant region antibody fusion proteins and compositions thereof
|
|
WO2015179823A2
|
|
Lung localized inhibitors of alpha(v)beta 6
|
|
KR20160093074A
|
|
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
KR20160062761A
|
|
Chimeric antigen receptor t cell switches and uses thereof
|
|
CN105829349A
|
|
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
